SCHEMBL1105134

SCHEMBL1105134

CCCC(=O)N(C)C(C)C(=O)OC1CC(=O)N(C)c2cc(cc(OC)c2Cl)C/C(C)=C/C=C/C(OC)C2(O)CC(OC(=O)N2)C(C)C2OC12C

nearest known ligand 0.87

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB4A P04350 4/20 0.87
TUBB P07437 4/20 0.87
TUBA3C P0DPH7 4/20 0.87
TUBA1B P68363 4/20 0.87
TUBA4A P68366 4/20 0.87
TUBB4B P68371 4/20 0.87
TUBB3 Q13509 4/20 0.87
TUBB2A Q13885 4/20 0.87
TUBB8 Q3ZCM7 4/20 0.87
TUBA3E Q6PEY2 4/20 0.87
TUBA1A Q71U36 4/20 0.87
TUBA1C Q9BQE3 4/20 0.87
TUBB6 Q9BUF5 4/20 0.87
TUBB2B Q9BVA1 4/20 0.87
TUBB1 Q9H4B7 4/20 0.87
CYP2D6 P10635 1/20 0.83
TSHR P16473 1/20 0.83
CYP2C19 P33261 1/20 0.83
HIF1A Q16665 1/20 0.83
P4HB P07237 1/20 0.73

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15444095 1.00 TUBB4A (0.87) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL27094854 1.00 TUBB4A (0.87) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL20382874 1.00 TUBB4A (0.87) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL25641500 1.00 TUBB4A (0.87) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL18123864 1.00 TUBB4A (0.87) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL23542054 1.00 TUBB4A (0.87) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL13312348 1.00 TUBB4A (0.87) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL17516495 1.00 TUBB4A (0.87) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL16103877 0.96 TUBB4A (0.88) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL22503914 0.96 TUBB4A (0.88) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230181755-A1 ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY CONJUGATES, TRIFLURIDINE AND TIPIRACIL SANOFI (FR) 2023-06-15 US disclosed
US-8987424-B2 CA6 antigen-specific cytotoxic conjugate and methods of using the same IMMUNOGEN, INC. (US) 2015-03-24 US disclosed
WO-2014134483-A2 CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS IMMUNOGEN, INC. (US) 2014-09-04 WO disclosed
US-8153765-B2 Anti-CD38 antibodies for the treatment of cancer Sanof Aventis (FR) 2012-04-10 US disclosed
US-20090099336-A1 using the conjugates in the inhibition of cell growth; cancer; monoclonal antibody or epitope-binding fragment thereof, that recognizes and binds the CA6 glycotope IMMUNOGEN INC. 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099336-A1 using the conjugates in the inhibition of cell growth; cancer; monoclonal antibody or epitope-binding fragment thereof, that recognizes and binds the CA6 glycotope CA6, CA14, CA13 TUBB4A 3340/4885TUBB 4079/4885TUBA3C 2911/4885
US-20230181755-A1 ANTITUMOR COMBINATIONS CONTAINING ANTI-CEACAM5 ANTIBODY CONJUGATES, TRIFLURIDINE AND TIPIRACIL TAS2R5, TMEM205, CD99 TUBB4A 853/4885TUBB 690/4885TUBA3C 348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.